Independent analyses of medical research are prized by doctors concerned about industry bias. Created in 1984, the United States Preventive Services Task Force (USPSTF) has earned a reputation for its independent, objective guidance on clinical preventive services, and many have long viewed its recommendations as a bulwark against the increasing excesses of these services.
However in 2009, the task force was the subject of a backlash after issuing an unenthusiastic "grade C" recommendation regarding routine mammography screening of women aged 40 to 49. In 2012, USPSTF found itself again in the hot seat following its "grade D" recommendation against routine prostate cancer screening. Grade D recommendations are issued when the task force finds "moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits."
Following these conservative recommendations, industry funded lobbying efforts resulted in Congress seeking to terminate the task force by cutting off funding to the Agency for Healthcare Research and Quality (AHRQ), the government agency that convenes the task force. Several bills attempted to "zero out" AHRQ's funding. 1 2 In December 2015, Congress sent a warning shot to the agency and cut 8% of its budget. 1 It is unclear what effects these threats have had. But in the past few years, the task force has issued several recommendations that are far more liberal in promoting interventions, which some experts say will lead to overtesting and overtreatment. [3] [4] [5] [6] [7] [8] In 2013, USPSTF recommended screening high risk smokers with low dose computed tomography screening. 9 In January and February 2016 it recommended routine depression screening for all adults and all teens, 10 11 and in November 2016 it recommended treatment with statins for primary prevention of cardiovascular disease, replacing its 2008 recommendation that addressed screening only and made no recommendations regarding statins. 12 The stakes are high. Task force recommendations are often used to develop clinical practice guidelines and serve as a basis for institutional quality assurance measures. Grade A and B recommendations also have financial implications, as US insurers are mandated by law to pay for these services (although not downstream expenses).
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Rigorous science?
Some task force recommendations rely on questionable research methodologies, including the use of "indirect" evidence; failure to include unpublished data; failure to check reported outcomes versus pre-specified outcomes; and, in at least one case, to have promulgated broad screening recommendations in the absence of a single randomised controlled screening trial (RCT).
Consider the task force's 2016 recommendation to screen all children aged 12 years and older and all adults for depression, including pregnant and postpartum women. 10 11 USPSTF assigned these recommendations a B grade, meaning that "there is high certainty that the net benefit is moderate or there is moderate certainty that the net benefit is moderate to substantial." The task force's recommendations are in contrast with Britain and Canada which recommend against routine screening. 14 15 However USPSTF's recommendations occurred in the absence of any RCTs assessing the health outcomes of screening versus not screening in children, and just one such trial in adults which reported that screening "leads to a modest increase in recognition rates, but does not have consistently positive effects on patient outcomes." 16 Brett Thombs, professor of psychiatry at McGill University, who has published research critical of the task force recommendations, 6 told The BMJ: "In the absence of any trial evidence that screening would benefit patients, there is real concern that these recommendations may lead to more harm than good."
Because there are no RCTs of depression screening versus no screening that show a health benefit, the task force relied on evidence from studies of the accuracy of screening tests and, separately, of depression treatment approaches. 6 John Ioannidis, one of Thombs' co-authors and professor of medicine at Stanford University, said that indirect evidence 
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should not even be considered screening evidence. He said it ignores the harms of screening and fails to take into account the sometimes important differences between the benefits of treating an individual with a clinically apparent condition compared with those who are detected only through screening. Ioannidis said that the harm-to-benefit ratios can vary greatly in these two populations.
Historically, indirect evidence has led to failed and harmful screening recommendations, according to Barnett Kramer, director of the division of cancer prevention at the National Cancer Institute, who told The BMJ that proponents of prostate cancer screening with the prostate specific antigen test and ovarian cancer screening with Ca-125 relied on "insufficient and weak indirect evidence." He said that subsequent direct evidence-using RCTs comparing screened and unscreened individuals-demonstrated that "the weight of evidence is that the harms are not likely to be exceeded by benefits." 17 18 (In 2012 USPSTF recommended against screening for these cancers. Both reviews are currently being updated. 17 19 )
Kirsten Bibbins-Domingo, current USPSTF chair and professor at University of California, San Francisco, said: "We evaluate the available evidence around preventive services by assessing a variety of valid trial designs and rigorously examining studies for potential bias. For adult depression, RCTs that randomized whether physicians received screening results showed positive outcomes. For children, the recommendation was made based on the strength of the evidence chain."
For non-elderly adults the USPSTF contends that four trials, in addition to the one that found no clinical outcome benefit, 16 are screening studies that support its recommendation. [20] [21] [22] [23] According to the task force, these trials "screened all patients for depression, enrolled only those screening positive, and returned results of screening to clinicians in the intervention group only." 10 The USPSTF told The BMJ that, if anything, this would have led to more conservative estimates of screening benefit. 24 Critics point out, however, that none of the four studies included an unscreened control group, and three of the studies compared optimized with usual care, meaning that any benefit in health outcomes could be because of optimized care and not screening (though not all found a benefit). [20] [21] [22] [23] The fourth study provided usual care to both arms but found that the intervention arm, in which providers were told of screening results, "did not lead to improved patient outcomes." 22 Wanda Filer, president of the American Academy of Family Physicians, told The BMJ that the academy supported the task force recommendations on depression screening. Responding to criticisms about their research methodology, she said, "It's not the job of the task force to create a research agenda; it's to look at what's out there and to make an interpretation. Is it perfect? No. And maybe more research is necessary, but they are dealing with the hand they were dealt."
Reliance on published, industry funded studies
A second concern stems from the fact that USPSTF recommendations have been based on evidence reviews that have not always included unpublished data.
Researchers who led the evidence reviews underlying the depression screening recommendations for children and non-pregnant adults told The BMJ that they did not request unpublished data from the US Food and Drug Administration (FDA) or the manufacturers-contrary to the agency's own guidance which states that "requests should be made to industry for additional sources of unpublished data." 25 Many systematic reviews, even outside USPSTF, do not include unpublished data from regulators and manufacturers. 26 However research by Erick Turner, a psychiatrist and former FDA reviewer, has highlighted the dangers of omitting unpublished data. In 2008 Turner showed that whereas FDA reviewers described 38 antidepressant studies as positive and 36 as negative or questionable, the published literature representing these same studies showed 48 studies as positive and a mere three as negative or questionable. 27 He told The BMJ that it was important to take steps to mitigate industry and publication bias when conducting reviews, saying, "Relying solely on selectively published, sponsor generated journal articles is a bit like relying on TV ads to tell you which kind of car is the best." Albert Siu, immediate past chair of the task force, defended its reliance on published data, telling The BMJ that although "publication bias is a very important question . . . it takes us 24 to 30 months from start to finish to release a report, and getting non-published information would drag this out for years." He later added by email, "The task force also relies on published data because it has been vetted by the peer review process, which-while imperfect-can address many sources of potential bias and methodological limitations that would be difficult to sort through independently."
But others rejected this logic. Jeffrey S Flier, former dean of Harvard Medical School, told The BMJ that although peer review is intended to improve the accuracy and truthfulness of published data, "a surprising amount of what we publish after peer review is still not true." Flier added that skilled reviewers who analyse unpublished data might be able to increase the likelihood that a conclusion is actually correct.
Carl Heneghan, professor of evidence based medicine at the University of Oxford added: "The assessment of evidence for treatment effects should not be undermined by reporting bias that occurs when evidence synthesis is based on journal publications alone. The major issue is the under-reporting of harms which has the effect to overestimate the net benefits."
The AHRQ, however, stands by Siu's position, stating that the agency "places the greatest weight on the published data."
The evidence report underlying USPSTF's statin recommendations has similar shortcomings. Roger Chou, professor of general internal medicine and director of the Pacific North west Evidence Based Practice Center, which conducted a systematic review of statins for the USPSTF, told The BMJ that they did not request data from the Cholesterol Treatment Trialists' (CTT) Collaboration because "CTT has not shared data in the past, so we did not expect that they would be willing to share data this time."
The evidence review led by Chou relied on 19 studies of primary prevention with statins compared with placebo or no statins. 12 The reviewers reported an absolute risk difference in all cause mortality of −0.40% (95% CI, −0.64% to −0.17%); however they were forced to rely almost entirely on published, industry funded studies (a single non-industry funded study weighted as contributing 0.2% of the mortality calculation was included). 8 28 Chou discounted the importance of obtaining the CTT data on statins for primary prevention, however, stating, "I don't think it is likely that having the individual patient data would change the findings-the results are very stable across studies and in multiple sensitivity and subgroup analyses."
Other limitations-each known to potentially inflate benefits-raise questions about the reliability of the task force recommendation: four of the 19 studies did not report FEATURE information on all cause mortality and therefore could not be included in the mortality calculation; one major trial was stopped early for benefit 29 30 ; and several of the 19 trials failed to specifically ask about common adverse effects of statins. 8 12 Despite these limitations, the task force issued a grade B recommendation for the use of statins in people aged 40 to 75 years without a history of cardiovascular disease and with one or more risk factors and a calculated 10 year risk score of 10% or greater.
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Outsourcing evidence reviews
The USPSTF generally does not conduct its own systematic reviews of the evidence, but often outsources the work to evidence based practice centers (EPCs), 31 after which it issues a recommendation.
The apparent liberalization of recent screening recommendations raises questions of whether financial conflicts could affect task force recommendations. However, The BMJ found that both USPSTF members and the individual EPC researchers selected to work on reviews were almost entirely free of financial conflicts.
Kenneth Lin, associate professor of family medicine at Georgetown University and former task force staffer, led the task force's in-house evidence review that led to the grade D recommendation against prostate cancer screening. An intense backlash followed.
Lin told The BMJ that negative reactions against earlier conservative recommendations may, however, affect how task force members interpret evidence-along with a desire not to "deprive" people of an option for screening that could be made free with a grade A or B recommendation.
AHRQ requires task force members and EPC researchers to disclose financial interests in excess of $1000 (£802; €941). The agency can manage such conflicts by requiring divestment, barring the individual from voting or participation, or by granting an exemption if the agency believes their expertise is necessary. 32 33 While individual task force and EPC members are mostly free of financial conflicts, several EPCs receive industry funding. This creates potential institutional conflicts of interest-research groups may be incentivized to accept study designs favoured by the sponsor in order to maintain funding streams. Over time, sponsors may shift contracts away from research groups that are too demanding about research design and award contracts to more pliant research groups. 34 35 Given the history of Congressional punishment of the AHRQ for publishing results believed to interfere with industry interests, conflicts at the institutional level-rather than individual researcher level-are of concern. 1 36 A spokesperson for RTI International-part of the RTI International-University of North Carolina EPC that provided an evidence review for the USPSTF's childhood depression screening recommendations-told The BMJ that RTI received around $161m of its $807m funding in 2014 from "commercial and non-governmental" sources. Kaiser's EPC-which conducted the adult depression review-gets 10% of its funding from industry, and another EPC, Duke Clinical Research Institute, receives 63.3% of its $331m annual revenue from industry.
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Too much medicine
Some experts contacted by The BMJ said that the USPSTF's advice for depression screening will lead to inappropriate treatment.
The task force acknowledged that the "evidence on treatment benefit for pregnant women is primarily for nonpharmacologic interventions (cognitive behavioral therapy, for example)," and that there is "evidence of potential serious fetal harms from pharmacologic treatment."
These cautions echo the findings of an EPC report commissioned by the AHRQ from the Pacific North west EPC based in Oregon Health and Science University. This EPC receives no industry funding. That review, led by Marian McDonagh, reported that "the majority of the evidence was indirect" and was "related to the use of selective serotonin reuptake inhibitors (SSRIs) taken during pregnancy [with]…little evidence" regarding the use of non-pharmacological interventions. 38 McDonagh and colleagues reported that data were mostly derived from observational studies of pregnant women who did and did not take antidepressants for any reason, and that "the proportions of women with depression in either group are rarely reported or analyzed."
The researchers said that they could not draw any conclusions about the effects of SSRIs on maternal depression or on its effects on the fetus or infant during pregnancy and breast feeding, as the evidence was "conflicting" and "insufficient."
Nonetheless, the USPSTF concluded that the "likelihood of these serious harms is low," and recommended screening for all pregnant and postnatal women. The task force added that "clinicians are encouraged to consider cognitive behavioral therapy or other evidence based counseling interventions when managing depression in pregnant or breastfeeding women," and that screening "should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up." Allen Frances, chair of the task force that wrote the Diagnostic and Statistical Manual (DSM-IV), and a well known critic of overdiagnosis, told The BMJ that current services for severely mentally ill people were already strained to bursting point. "We don't need to create an army of mislabeled healthy people. We should first take adequate care of people who are already sick and in urgent need." 7 Alan Roth, chair of the primary care council of the Right Care Alliance, a non-profit organization based in Boston that works to ensure patients are neither undertreated nor overtreated, raised similar concerns. He told The BMJ that he often saw poor and middle class patients who were unable to access mental health services. 39 40 He said that depression screening tests-some of which, like Pfizer's PHQ2 and PHQ9 tests, are made by companies that manufacture antidepressants-are "certainly very sensitive but we know they're not very specific." Without adequate services in place to detect false positive test results and to provide non-drug treatment, Roth said that screening tests were likely to drive overtreatment with antidepressants. 41 42 A better way forward Some experts say that before making population based screening and prevention recommendations independent researchers should analyze more forms of raw data such as clinical study reports and patient level data, as was performed for the Cochrane review of oseltamivir and the paroxetine Study 329 re-analysis. 43 44 For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
When such rigoros analyses are not possible, it is important to acknowledge the resulting uncertainty, says Heneghan, who co-authored the Cochrane review. Heneghan told The BMJ that clinical practice recommendations "should ideally aim to reduce uncertainty around practice based interventions and increase the quality of care; but use of low quality evidence often has the opposite effect."
He added, "In the face of no evidence, or very low quality evidence, guideline writers should refrain from making recommendations. Indeed many guideline bodies would better serve clinical practice by making fewer recommendations: reflecting more of the uncertainty around treatment decisions. What we need are fewer recommendations and more high quality evidence to base decisions on. Currently we seem to be seeing the exact opposite."
In light of the AHRQ's critical role in making screening and prevention recommendations, better funding of the agency could enhance its ability to conduct in-depth and in-house analyses that would be less subject to the demands of industry and more responsive to the public interest.
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